This summer, Bausch + Lomb unveiled plans to acquire a dry eye disease treatment from Novartis for up to $2.5 billion. Now, the eye health company has closed the deal. The purchase of XIIDRA, a 5% a ...
Novartis last year bought Shire’s dry eye drug Xiidra from Takeda to beef up its ophthalmic offerings and reap blockbuster sales along the way. But now, the $3 billion-plus buy doesn't look so ...
Novartis buys Takeda’s Xiidra for upwards of $5.3B: 3 details Swedish pharmaceutical company Novartis bought Xiidra, a drug for dry eyes, from Japanese pharmaceutical company Takeda for $3.4 billion ...
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has entered ...
Hosted on MSN
Bausch + Lomb publishes results from Xiidra 5% study
Bausch + Lomb (BLCO) announced Clinical Ophthalmology has published results from an investigator-initiated study which evaluated the effectiveness of Xiidra 5% in alleviating end-of-day eye dryness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback